Showing 141 - 160 results of 5,745 for search '(( decrease stress resistance ) OR ( decrease ((therapy resistance) OR (therapeutic resistance)) ))', query time: 0.26s Refine Results
  1. 141
  2. 142

    DataSheet1_A flavonoid-rich fraction of Euphorbia peplus attenuates hyperglycemia, insulin resistance, and oxidative stress in a type 2 diabetes rat model.docx by Reem S. Alruhaimi (16381122)

    Published 2023
    “…<p>Background: Type 2 diabetes (T2D) is a metabolic disorder characterized by insulin resistance (IR) and hyperglycemia. Plants are valuable sources of therapeutic agents for the management of T2D. …”
  3. 143

    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf by Bo Li (112195)

    Published 2021
    “…However, the rapid emergence of resistance toward doxorubicin threatens its clinical application, thus the need for combination therapy. …”
  4. 144

    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf by Bo Li (112195)

    Published 2023
    “…However, the rapid emergence of resistance toward doxorubicin threatens its clinical application, thus the need for combination therapy. …”
  5. 145

    DataSheet_1_Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.pdf by Bo Li (112195)

    Published 2021
    “…However, the rapid emergence of resistance toward doxorubicin threatens its clinical application, thus the need for combination therapy. …”
  6. 146

    DataSheet_1_DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small... by Mingyue Liu (1519720)

    Published 2022
    “…In conclusion, these results demonstrated that DHW-221, as a novel P-gp inhibitor, represents a prospective therapeutic candidate to overcome MDR in Taxol-resistant NSCLC treatment.…”
  7. 147

    DataSheet_1_Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma.docx by Yan Zhuang (115199)

    Published 2023
    “…</p>Results<p>Our findings revealed a consistent decrease in the levels of complement components in the pomalidomide-resistant group. …”
  8. 148
  9. 149
  10. 150
  11. 151

    Presentation_1_Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter... by Mei-Ling Han (1612951)

    Published 2019
    “…<p>Background: Polymyxins are a last-line class of antibiotics against multidrug-resistant Acinetobacter baumannii. However, polymyxin resistance can emerge with monotherapy, highlighting the need for synergistic combination therapies. …”
  12. 152
  13. 153
  14. 154
  15. 155
  16. 156

    Image_4_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg by Mona M. Al-Gizawiy (17787488)

    Published 2024
    “…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …”
  17. 157

    Image_6_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg by Mona M. Al-Gizawiy (17787488)

    Published 2024
    “…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …”
  18. 158

    Image_1_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg by Mona M. Al-Gizawiy (17787488)

    Published 2024
    “…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …”
  19. 159

    Image_5_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg by Mona M. Al-Gizawiy (17787488)

    Published 2024
    “…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …”
  20. 160

    Image_2_Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.jpeg by Mona M. Al-Gizawiy (17787488)

    Published 2024
    “…Background<p>Treatment-resistant glioblastoma (trGBM) is an aggressive brain tumor with a dismal prognosis, underscoring the need for better treatment options. …”